Target Information

Target General Infomation
Target ID
T49493
Former ID
TTDS00498
Target Name
Hemoglobin
Gene Name
HBA2
Synonyms
Beta-globin; HBB; Hemoglobin beta chain; LVV-hemorphin-7; HBA2
Target Type
Successful
Disease Alopecia [ICD9: 704.09; ICD10: L65.9]
Anemia [ICD9: 280-285; ICD10: D50-D64]
Blood transfusion [ICD10: D50-D89]
Blood forming organ disorders [ICD10: D75.9]
Beta thalassemia [ICD10: D56.1]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Cardiovascular disorder [ICD10: I00-I99]
Chronic myelogenous leukaemia [ICD9: 205.1; ICD10: C92.1]
Hematopoietic [ICD10: D50-D89]
Hypotension [ICD9: 458, 796.3; ICD10: I95]
Iron overload [ICD10: R79.0]
Iron deficiency anaemia [ICD10: D50]
Iron-deficiency anemia [ICD9: 280; ICD10: D50]
Lung cancer [ICD9: 162; ICD10: C33-C34]
Liver cancer [ICD9: 140-229, 155, 203.0; ICD10: C22]
Reperfusion injury [ICD10: I00-I99]
Function
Involved in oxygen transport from the lung to the various peripheral tissues. Lvv-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.
BioChemical Class
Globin family
Target Validation
T49493
UniProt ID
P69905
Sequence
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG
KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP
AVHASLDKFLASVSTVLTSKYR
Structure
1A00; 1A01; 1A0U; 1A0Z; 1A3N; 1A3O; 1A9W; 1ABW; 1ABY; 1AJ9; 1B86; 1BAB; 1BBB; 1BIJ; 1BUW; 1BZ0; 1BZ1; 1BZZ; 1C7B; 1C7C; 1C7D; 1CLS; 1CMY; 1COH; 1DKE; 1DXT; 1DXU; 1DXV; 1FDH; 1FN3; 1G9V; 1GBU; 1GBV; 1GLI; 1GZX; 1HAB; 1HAC; 1HBA; 1HBB; 1HBS; 1HCO; 1HDB; 1HGA; 1HGB; 1HGC; 1HHO; 1IRD; 1J3Y; 1J3Z; 1J40; 1J41; 1J7S; 1J7W; 1J7Y; 1JY7; 1K0Y; 1K1K; 1KD2; 1LFL; 1LFQ; 1LFT; 1LFV; 1LFY; 1LFZ; 1LJW; 1M9P; 1MKO; 1NEJ; 1NIH; 1NQP; 1O1I; 1O1J; 1O1K; 1O1L; 1O1M; 1O1N; 1O1O; 1O1P; 1QI8; 1QSH;1QSI; 1QXD; 1QXE; 1R1X; 1R1Y; 1RPS; 1RQ3; 1RQ4; 1RQA; 1RVW; 1SDK; 1SDL; 1SHR; 1SI4; 1THB; 1UIW; 1VWT; 1XXT; 1XY0; 1XYE; 1XZ2; 1XZ4; 1XZ5; 1XZ7; 1XZU; 1XZV; 1Y01; 1Y09; 1Y0A; 1Y0C; 1Y0D; 1Y0T; 1Y0W; 1Y22; 1Y2Z; 1Y31; 1Y35; 1Y45; 1Y46; 1Y4B; 1Y4F; 1Y4G; 1Y4P; 1Y4Q; 1Y4R; 1Y4V; 1Y5F; 1Y5J; 1Y5K; 1Y7C; 1Y7D; 1Y7G; 1Y7Z; 1Y83; 1Y85; 1Y8W; 1YDZ; 1YE0; 1YE1; 1YE2; 1YEN; 1YEO; 1YEQ; 1YEU; 1YEV; 1YFF; 1YG5; 1YGD; 1YGF; 1YH9; 1YHE; 1YHR; 1YIE; 1YIH; 1YVQ; 1YVT; 1YZI; 1Z8U; 2D5Z; 2D60; 2DN1; 2DN2; 2DN3; 2DXM; 2H35; 2HBC; 2HBD; 2HBE; 2HBF; 2HBS; 2HCO; 2HHB; 2HHD; 2HHE; 2M6Z; 2W6V; 2W72; 2YRS; 3B75; 3D17;3D7O; 3DUT; 3HHB; 3HXN; 3IA3; 3IC0; 3IC2; 3KMF; 3NL7; 3NMM; 3ODQ; 3ONZ; 3OO4; 3OO5; 3OVU; 3P5Q; 3QJB; 3QJC; 3QJD; 3QJE; 3R5I; 3S48; 3S65; 3S66; 3SZK; 3WCP; 3WHM; 4FC3; 4HHB; 4IJ2; 4L7Y; 4M4A; 4M4B; 4MQC; 4MQG; 4MQH; 4MQI; 4MQJ; 4MQK; 4N7N; 4N7O; 4N7P; 4N8T; 4NI0; 4NI1; 4WJG; 4X0I; 4X0L; 6HBW; 1A00; 1A01; 1A0U; 1A0Z; 1A3N; 1A3O; 1ABW; 1ABY; 1AJ9; 1B86; 1BAB; 1BBB; 1BIJ; 1BUW; 1BZ0; 1BZ1; 1BZZ; 1C7B; 1C7C; 1C7D; 1CBL; 1CBM; 1CH4; 1CLS; 1CMY; 1COH; 1DKE; 1DXT; 1DXU; 1DXV; 1FN3; 1G9V; 1GBU; 1GBV; 1GLI; 1GZX; 1HAB; 1HAC; 1HBA; 1HBB; 1HBS; 1HCO; 1HDB; 1HGA; 1HGB; 1HGC; 1HHO; 1IRD; 1J3Y; 1J3Z; 1J40; 1J41; 1J7S; 1J7W; 1J7Y; 1JY7; 1K0Y; 1K1K; 1KD2; 1LFL; 1LFQ; 1LFT; 1LFV; 1LFY; 1LFZ;1LJW; 1M9P; 1MKO; 1NEJ; 1NIH; 1NQP; 1O1I; 1O1J; 1O1K; 1O1L; 1O1M; 1O1N; 1O1O; 1O1P; 1QI8; 1QSH; 1QSI; 1QXD; 1QXE; 1R1X; 1R1Y; 1RPS; 1RQ3; 1RQ4; 1RQA; 1RVW; 1SDK; 1SDL; 1THB; 1UIW; 1VWT; 1XXT; 1XY0; 1XYE; 1XZ2; 1XZ4; 1XZ5; 1XZ7; 1XZU; 1XZV; 1Y09; 1Y0A; 1Y0C; 1Y0D; 1Y0T; 1Y0W; 1Y22; 1Y2Z; 1Y31; 1Y35; 1Y45; 1Y46; 1Y4B; 1Y4F; 1Y4G; 1Y4P; 1Y4Q; 1Y4R; 1Y4V; 1Y5F; 1Y5J; 1Y5K; 1Y7C; 1Y7D; 1Y7G; 1Y7Z; 1Y83; 1Y85; 1Y8W; 1YDZ; 1YE0; 1YE1; 1YE2; 1YEN; 1YEO; 1YEQ; 1YEU; 1YEV; 1YFF; 1YG5; 1YGD; 1YGF; 1YH9; 1YHE; 1YHR; 1YIE; 1YIH; 1YVQ; 1YVT; 1YZI; 2D5Z; 2D60; 2DN1; 2DN2; 2DN3; 2DXM; 2H35; 2HBC; 2HBD; 2HBE;2HBF; 2HBS; 2HCO; 2HHB; 2HHD; 2HHE; 2M6Z; 2W6V; 2W72; 2YRS; 3B75; 3D17; 3D7O; 3DUT; 3HHB; 3HXN; 3IC0; 3IC2; 3KMF; 3NL7; 3NMM; 3ODQ; 3ONZ; 3OO4; 3OO5; 3P5Q; 3QJB; 3QJC; 3QJD; 3QJE; 3R5I; 3S65; 3S66; 3SZK; 3W4U; 3WCP; 3WHM; 4FC3; 4HHB; 4IJ2; 4L7Y; 4M4A; 4M4B; 4MQC; 4MQG; 4MQH; 4MQI; 4N7N; 4N7O; 4N7P; 4N8T; 4NI0; 4NI1; 4WJG; 4X0I; 4X0L; 6HBW
Drugs and Mode of Action
Drug(s) Iron Drug Info Approved Iron-deficiency anemia [552002]
Iron Dextran Drug Info Approved Iron deficiency anaemia [538437], [551871]
Efaproxyn Drug Info Phase 3 Lung cancer [521598]
PolyHeme Drug Info Phase 3 Blood forming organ disorders [521584]
Hemoglobin raffimer Drug Info Phase 2/3 Anemia [521517]
5-hydroxymethyl-2-furfural (sickle cell disease), AesRx LLC Drug Info Phase 2 Anemia [524529]
FBS-0701 Drug Info Phase 2 Iron overload [523142]
HQK-1001 Drug Info Phase 2 Beta thalassemia [525404]
Iron Drug Info Phase 2 Iron deficiency anaemia [551871]
OXY-111A Drug Info Phase 1/2 Cardiovascular disorder [525298]
Hemoximer Drug Info Discontinued in Phase 3 Hypotension [546525]
VX-366 Drug Info Discontinued in Phase 2 Hematopoietic [546039]
HRC-302 Drug Info Discontinued in Phase 1 Chronic myelogenous leukaemia [547281]
AN-10 Drug Info Terminated Alopecia [546433]
Diaspirin crosslinked hemoglobin Drug Info Terminated Cerebrovascular ischaemia [545936]
HRC-101 Drug Info Terminated Blood transfusion [547440]
HRC-102 Drug Info Terminated Reperfusion injury [547482]
HRC-201 Drug Info Terminated Liver cancer [547896]
RHb1.1 Drug Info Terminated Anemia [546469]
Inhibitor 1,3,5-BENZENETRICARBOXYLIC ACID Drug Info [551374]
2,6-DICARBOXYNAPHTHALENE Drug Info [551374]
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine Drug Info [551374]
4-Carboxycinnamic Acid Drug Info [551374]
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine Drug Info [551374]
Efaproxyn Drug Info [527506]
Heme Drug Info [551374]
SEBACIC ACID Drug Info [551374]
VX-366 Drug Info [525637]
Modulator 5-hydroxymethyl-2-furfural (sickle cell disease), AesRx LLC Drug Info [527406]
AN-10 Drug Info [551826]
Diaspirin crosslinked hemoglobin Drug Info [530709]
FBS-0701 Drug Info [525388]
Hemoglobin raffimer Drug Info [527505]
HRC-101 Drug Info [528970]
HRC-102 Drug Info [550172]
HRC-302 Drug Info [547282]
PolyHeme Drug Info [544047]
RHb1.1 Drug Info [527399]
Antagonist Hemoximer Drug Info [550037]
Inducer HQK-1001 Drug Info [532549]
Enhancer HRC-201 Drug Info [550172]
OXY-111A Drug Info [534711]
Activator Iron Drug Info [536828]
Iron Dextran Drug Info [536828]
Pathways
KEGG Pathway African trypanosomiasis
Malaria
Reactome Erythrocytes take up carbon dioxide and release oxygen
Erythrocytes take up oxygen and release carbon dioxide
Scavenging of heme from plasma
WikiPathways Binding and Uptake of Ligands by Scavenger Receptors
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes
Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes
Factors involved in megakaryocyte development and platelet production
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 521517ClinicalTrials.gov (NCT00038454) Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery. U.S. National Institutes of Health.
Ref 521584ClinicalTrials.gov (NCT00076648) Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting. U.S. National Institutes of Health.
Ref 521598ClinicalTrials.gov (NCT00083304) Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer. U.S. National Institutes of Health.
Ref 523142ClinicalTrials.gov (NCT01186419) Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload. U.S. National Institutes of Health.
Ref 524529ClinicalTrials.gov (NCT01987908) Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease. U.S. National Institutes of Health.
Ref 525298ClinicalTrials.gov (NCT02528526) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm.
Ref 525404A phase 2 trial of HQK-1001 in HbE-beta thalassemia demonstrates HbF induction and reduced anemia. Blood. 2014 Mar 20;123(12):1956-7.
Ref 538437FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010787.
Ref 545936Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005412)
Ref 546039Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006007)
Ref 546433Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008114)
Ref 546469Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008362)
Ref 546525Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008774)
Ref 547281Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014790)
Ref 547440Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016356)
Ref 547482Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016740)
Ref 547896Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020214)
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 552002Drug information of Iron, 2008. eduDrugs.
Ref 525388A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
Ref 525637A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents. Blood Cells Mol Dis. 1999 Jun-Aug;25(3-4):255-69.
Ref 527399Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med. 2005 Jan;145(1):21-32.
Ref 5274065-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
Ref 527505Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
Ref 527506Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
Ref 528970The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease. Anesthesiology. 2007 Aug;107(2):281-7.
Ref 530709Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010 May;68(5):1158-71.
Ref 532549A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
Ref 534711Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
Ref 536828Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
Ref 544047Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
Ref 547282Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014790)
Ref 550037Effect of NaBH4 Concentration and Reaction Time on Physical Properties of Glutaraldehyde-Polymerized Hemoglobin. Biotechnology Progress. 05/2004; 20(3):946-52.
Ref 550172WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 551374The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
Ref 551826Genes for Development, Cell Growth and Infectious Diseases, Gabriel Gachelin, 1995. Page(215).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.